In the last trading session, 1.17 million Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) shares changed hands as the company’s beta touched -0.94. With the company’s per share price at $12.91 changed hands at $0.84 or 6.96% during last session, the market valuation stood at $871.55M. AMLX’s last price was a discount, traded about -224.79% off its 52-week high of $41.93. The share price had its 52-week low at $11.82, which suggests the last value was 8.44% up since then. When we look at Amylyx Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 3.04 million shares, with the 3-month average coming to 1.52 million.

Analysts gave the Amylyx Pharmaceuticals Inc (AMLX) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AMLX as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Amylyx Pharmaceuticals Inc’s EPS for the current quarter is expected to be $0.18.

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) trade information

Instantly AMLX was in green as seen at the end of in last trading. With action -0.23%, the performance over the past five days has been red. The jump to weekly highs of 13.42 on Monday, 11/20/23 added 6.96% to the stock’s daily price. The company’s shares are showing year-to-date downside of -65.06%, with the 5-day performance at -0.23% in the red. However, in the 30-day time frame, Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) is -23.34% down. Looking at the short shares, we see there were 7.93 million shares sold at short interest cover period of 5.31 days.

The consensus price target for the stock as assigned by Wall Street analysts is $39.40, meaning bulls need an upside of 67.23% from its current market value. According to analyst projections, AMLX’s forecast low is $27.00 with $46.00 as the target high. To hit the forecast high, the stock’s price needs a -256.31% plunge from its current level, while the stock would need to soar -109.14% for it to hit the projected low.

Amylyx Pharmaceuticals Inc (AMLX) estimates and forecasts

Data shows that the Amylyx Pharmaceuticals Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -52.31% over the past 6 months, a 125.07% in annual growth rate that is considerably higher than the industry average of 11.30%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Amylyx Pharmaceuticals Inc will rise 127.70%, while the growth in revenue is estimated to hit 1,000.00% for the next quarter. Year-over-year growth is forecast to reach 1,612.60% up from the last financial year.

Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of $107.85 million. 1 analysts are of the opinion that Amylyx Pharmaceuticals Inc’s revenue for the quarter ending Mar 2024 will be $112.25 million. The company’s revenue for the corresponding quarters a year ago was $21.89 million and $71.43 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 392.80%. The estimates for the next quarter sales put growth at 57.20%.

The 2023 estimates are for Amylyx Pharmaceuticals Inc earnings to increase by 128.32%.

AMLX Dividends

Amylyx Pharmaceuticals Inc is expected to release its next quarterly earnings report on November 09.

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 22.79% of Amylyx Pharmaceuticals Inc shares while 85.44% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 110.65%. There are 85.44% institutions holding the Amylyx Pharmaceuticals Inc stock share, with Vanguard Group Inc the top institutional holder. As of Jun 29, 2023, the company held 7.31% of the shares, roughly 4.93 million AMLX shares worth $106.25 million.

Perceptive Advisors Llc holds the second largest percentage of outstanding shares, with 7.23% or 4.87 million shares worth $105.13 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. With 1.66 million shares estimated at $35.78 million under it, the former controlled 2.46% of total outstanding shares. On the other hand, Vanguard Small-Cap Index Fund held about 2.06% of the shares, roughly 1.39 million shares worth around $29.93 million.